Two BCG vaccine formulations prepared from the same strain with different J774 macrophage activation capacities and patterns of NF-kappaB induction.
Two BCG vaccine formulations of the Moreau strain, commercially manufactured for anti-tuberculosis vaccination, ID-BCG, or anti-cancer adjuvant therapy, Onco-BCG, were compared for immunogenic activity in vitro. The growth rates of both vaccines in murine macrophages were the same, however, Onco-BCG induced stronger and longer-lasting secretion of TNF-alpha, IL-6 and nitric oxide. Onco-vaccine was also more potent in inducing NF-kappaB p65/p50 DNA-binding activity whilst in ID-BCG-infected cells the activity was transient and then gradually replaced by the transcriptionally inactive homodimer p50/p50. Comparative analysis of mycobacterial antigens of the two vaccines demonstrated a difference in expression of the 19 kDa and 38 kDa lipoproteins detected only in Onco-BCG extracts. These results suggest that these molecules may be responsible for the vigorous activation of macrophages induced by the Onco-vaccine. The data obtained show that vaccines from the same BCG strain, when manufactured differently, can vary significantly in their antigen expression and, consequently, in their capacity for macrophage activation which could contribute to the difference in their immunopotentiating effects.